AMGN

AstraZeneca and Amgen collaborate on treatments for inflammatory diseases

AstraZeneca (NYSE:AZN) and Amgen (NYSE:AMGN) will collaborate on five monoclonal antibodies to treat inflammatory diseases in a move that could help AstraZeneca steer away from the patent cliff and put recent setbacks behind. The pharmaceutical companies will jointly develop and commercialize five Amgen drugs. AstraZeneca will pay an initial $50 million up front and shoulder […]

By Stephanie Baum

Pharma

FDA eases restrictions on GSK’s Promacta, Amgen’s Nplate

For the last three years, doctors prescribing the low-platelet drugs Promacta or Nplate were required to follow a strict regimen. The doctor, the pharmacist and the patient had to enroll in a monitoring program for the drugs. Doctors regularly collected and reported information on any adverse drug reactions. Due to safety concerns, the U.S. Food […]

By Frank Vinluan

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

A Personalized Approach to Medication Nonadherence

At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.

AstraZeneca and Amgen collaborate on treatments for inflammatory diseases

FDA eases restrictions on GSK’s Promacta, Amgen’s Nplate

When Investment Rhymes with Canada